Antipsychotic drug use and the risk of venous thromboembolism in elderly patients with dementia

Journal of Clinical Psychopharmacology

Volumn 33, Issue 6, 2013, Pages 753-758

  Schmedt, Niklas ^a   Garbe, Edeltraut ^a,b  

^a LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

^b UNIVERSITY OF BREMEN   (Germany)

Author keywords

adverse drug reaction; antipsychotics; dementia,elderly patients; venous thromboembolism

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENPERIDOL; CHLORPROTHIXENE; FLUPENTIXOL; FLUPHENAZINE; FLUSPIRILENE; HALOPERIDOL; LEVOMEPROMAZINE; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIPAMPERONE; PROMETHAZINE; PROTHIPENDYL; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TIAPRIDE; ZIPRASIDONE; ZUCLOPENTHIXOL;

AGED; ARTICLE; BIPOLAR DISORDER; CASE CONTROL STUDY; CONTROLLED STUDY; DATA BASE; DEEP VEIN THROMBOSIS; DEMENTIA; DIABETES MELLITUS; DRUG EXPOSURE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEALTH INSURANCE; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OBESITY; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; VARICOSIS; VEIN INSUFFICIENCY; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; DATABASES, FACTUAL; DEMENTIA; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK FACTORS; TIME FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84888134822     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182a412d5     Document Type: Article

References (50)

1. Kales HC, Zivin K, Kim HM, et al. Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry. 2011;68:190-197.
2. Guthrie B, Clark SA, McCowan C. The burden of psychotropic drug prescribing in people with dementia: a population database study. Age Ageing. 2010;39:637-642.
3. Wetzels RB, Zuidema SU, de Jonghe JF, et al. Prescribing pattern of psychotropic drugs in nursing home residents with dementia. Int Psychogeriatr. 2011;23:1249-1259.
4. Shah SM, Carey IM, Harris T, et al. Antipsychotic prescribing to older people living in care homes and the community in England and Wales. Int J Geriatr Psychiatry. 2011;26:423-434.
5. Majic T, Pluta JP, Mell T, et al. The pharmacotherapy of neuropsychiatric symptoms of dementia: a cross-sectional study in 18 homes for the elderly in Berlin. Dtsch Arztebl Int. 2010;107:320-327.
6. Kamble P, Chen H, Sherer J, et al. Antipsychotic drug use among elderly nursing home residents in the United States. Am J Geriatr Pharmacother. 2008;6:187-197.
7. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306:1359-1369.
8. Maher AR, Theodore G. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm. 2012;18(5 suppl B):S1-S20.
9. Trifiro G, Spina E, Gambassi G. Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? Pharmacol Res. 2009;59:1-12.
10. Pratt NL, Roughead EE, Ramsay E, et al. Risk of hospitalization for stroke associated with antipsychotic use in the elderly: a self-controlled case series. Drugs Aging. 2010;27:885-893.
11. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337:a1227.
12. Wang S, Linkletter C, Dore D, et al. Age, antipsychotics, and the risk of ischemic stroke in the Veterans Health Administration. Stroke. 2012;43:28-31.
13. Sacchetti E, Turrina C, Valsecchi P. Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review. Drug Saf. 2010;33:273-288.
14. Pariente A, Fourrier-Reglat A, Ducruet T, et al. Antipsychotic use and myocardial infarction in older patients with treated dementia. Arch Intern Med. 2012;172:648-653.
15. Trifiro G, Gambassi G, Sen EF, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Ann Intern Med. 2010;152:418-440.
16. Star K, Bate A, Meyboom RH, et al. Pneumonia following antipsychotic prescriptions in electronic health records: a patient safety concern? Br J Gen Pract. 2010;60:e385-e394.
17. Pratt N, Roughead E, Salter A, et al. Factors associated with choice of antipsychotic treatment in elderly veterans: potential confounders for observational studies. Aust N Z J Public Health. 2010;34:589-593.
18. Lipscombe LL, Levesque LE, Gruneir A, et al. Antipsychotic drugs and the risk of hyperglycemia in older adults without diabetes: a population-based observational study. Am J Geriatr Psychiatry. 2011;19:1026-1033.
19. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225-235.
20. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146:775-786.
21. Huybrechts KF, Gerhard T, Crystal S, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ. 2012;344:e977.
22. Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176:627-632.
23. Liperoti R, Onder G, Landi F, et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psychiatry. 2009;70:1340-1347.
24. Huybrechts KF, Rothman KJ, Silliman RA, et al. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ. 2011;183:411-419.
25. Chaggar PS, Shaw SM, Williams SG. Effect of antipsychotic medications on glucose and lipid levels. J Clin Pharmacol. 2011;51:631-638.
26. Canoso RT, de Oliveira RM, Nixon RA. Neuroleptic-associated autoantibodies. A prevalence study. Biol Psychiatry. 1990;27:863-870.
27. Axelsson S, Hagg S, Eriksson AC, et al. In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation. Clin Exp Pharmacol Physiol. 2007;34:775-780.
28. Orr MW, Knox JM, Allen R, et al. The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients. Br J Clin Pharmacol. 1981;11:255-259.
29. Hagg S, Jonsson AK, Spigset O. Risk of venous thromboembolism due to antipsychotic drug therapy. Expert Opin Drug Saf. 2009;8:537-547.
30. Ray JG, Mamdani MM, Yeo EL. Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism. Thromb Haemost. 2002;88:205-209.
31. Liperoti R, Pedone C, Lapane KL, et al. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med. 2005;165:2677-2682.
32. Kleijer BC, Heerdink ER, Egberts TC, et al. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients. J Clin Psychopharmacol. 2010;30:526-530.
33. Beekmann M, van den Bussche H, Glaeske G, et al. Geriatric morbidity patterns and need for long-term care in patients with dementia [in German]. Psychiatr Prax. 2012;39:222-227.
34. Pigeot I, Ahrens W. Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. Pharmacoepidemiol Drug Saf. 2008;17:215-223.
35. Garbe E, Suling M, Kloss S, et al. Linkage of mother-baby pairs in the German Pharmacoepidemiological Research Database. Pharmacoepidemiol Drug Saf. 2011;20:258-264.
36. Schink T, Behr S, Garbe E. Externe Validierung von Verschreibungsdaten nichtsteroidaler Antirheumatika anhand des Arzneiverordnungsreports.54. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (gmds). Essen, 2009. Available at: http://www.egms.de/static/de/meetings/gmds2009/09gmds281.shtml. Accessed February 27, 2013.
37. Rothman K, Greenland S, Lash T. Case-control studies. In: Rothman K, Greenland S, Lash T, eds. Modern Epidemiology. 3rd ed. Philadelphia, PA: Wolters Kluwer, Lippincott Williams & Wilkins; 2008:111-127.
38. Masopust J, Maly R, Andrys C, et al. Markers of thrombogenesis are activated in unmedicated patients with acute psychosis: a matched case control study. BMC Psychiatry. 2011;11:2.
39. Allenet B, Schmidlin S, Genty C, et al. Antipsychotic drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf. 2011;21:42-48
40. Jonsson AK, Horvath-Puho E, Hagg S, et al. Antipsychotics and risk of venous thromboembolism: a population-based case-control study. Clin Epidemiol. 2009;1:19-26.
41. Lacut K. Association between antipsychotic drugs, antidepressant drugs, and venous thromboembolism. Clin Adv Hematol Oncol. 2008;6:887-890.
42. Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ. 2010;341:c4245.
43. Parkin L, Skegg DC, Herbison GP, et al. Psychotropic drugs and fatal pulmonary embolism. Pharmacoepidemiol Drug Saf. 2003;12:647-652.
44. Zhang R, Dong L, Shao F, et al. Antipsychotics and venous thromboembolism risk: a meta-analysis. Pharmacopsychiatry. 2011;44:183-188.
45. Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology. 1997;8:671-677.
46. Broekema WJ, de Groot IW, van Harten PN. Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergicsVa European study. Pharm World Sci. 2007;29:126-130.
47. White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 suppl 1):I4-I8.
48. Schneeweiss S, Rassen JA, Glynn RJ, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20:512-522.
49. Goldhaber SZ. Risk factors for venous thromboembolism. J Am Coll Cardiol. 2010;56:1-7.
50. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809-815.